NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma
ConditionNon Hodgkin Lymphoma (NHL)
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19-80
SponsorNOBO Medicine
About this trial
This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed/refractory NHL including FL, MCL and MZL
Eligibility criteria
Qualifiers
Age 19 to 80 years.
Patients must voluntarily agree to participate in the study and provide written informed consent prior to any study-related procedures.
Patients with histologically confirmed follicular lymphoma, mantle cell lymphoma or marginal zone lymphoma.
relapsed/refractory Patients who have received more than two prior lines of therapy.
Disqualifiers
Previous treatment with NB02 (poseltinib).
Patients who have experienced progression on BTKi mono or BTKi containing regimen (However, patients who discontinued treatment due to adverse-effect-related intolerance or for economic or social reasons remain eligible for enrollment).
Unable to take oral medication.
Inability to comply with study and follow-up procedures.
Trial design
Treatments tested in this trial
- NB02 (Poseltinib)
Treatment groups
9 Participants
are divided into 1 treatment groupLocations
6Chonnam National University Hwasun Hospital Hwasun South Korea
Seoul National University Bundang Hospital Seongnam South Korea
Catholic univ of Yeouido St Mary's Hospital Seoul South Korea
Samsung Medical Center Seoul South Korea
Sponsors and collaborators
NOBO Medicine
Lead sponsor
Source ClinicalTrials.gov